Open Label Trial of Rapastinel (Formerly GLYX-13) in Individuals With Obsessive-Compulsive Disorder

Trial Profile

Open Label Trial of Rapastinel (Formerly GLYX-13) in Individuals With Obsessive-Compulsive Disorder

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Rapastinel (Primary)
  • Indications Obsessive-compulsive disorders
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 09 Feb 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
    • 16 Apr 2015 Treatment arms changed from 2 to1 as reported by ClinicalTrials.gov record.
    • 16 Apr 2015 Planned number of patients changed from 45 to 20 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top